Skip to main content
Triangle logo TriangleGet started

Nal-IRI (NCT04150640)

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma: a one-minute explainerNCT041506401 min

Nal-IRI trial for Esophageal Adenocarcinoma (NCT04150640). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults starting systemic therapy for locally advanced or metastatic esophageal or gastric adenocarcinoma. HER2 and PD-L1 status must be known.

The idea: all cohorts receive fluorouracil, oxaliplatin, and liposomal irinotecan. Oxaliplatin damages DNA. HER2-positive cohorts add trastuzumab, targeting HER2; one adds pembrolizumab. One HER2-negative cohort adds nivolumab. The latter two drugs release a PD1 immune brake. Treatment schedules differ by cohort. Researchers measure tumor response or safety, depending on the group.

This phase 2 study plans 52 patients. Nataliya Uboha leads at Wisconsin, Madison, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.